The 25th China Hospital Construction Conference & International Hospital Build and Infrastructure Exposition (CHCC20...
Bridge Biotherapeutics, a startup based in the Republic of Korea and the US, has entered into a joint research agreement...
China Pharma Holdings, Inc., an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsi...
Merck, known as MSD outside of the United States and Canada, and Curon Biopharmaceutical, a China-based biotechnology st...
An interdisciplinary team from the Li Ka Shing Faculty of Medicine of the University of Hong Kong (HKUMed) has developed...
Apexelsin, a generic drug from China been approved by the European Commission. Apexelsin is a generic dru...
Porton Advanced Solutions, a subsidiary of the globally recognised contract development and manufacturing org...
Professor Chung-mau Lo, Secretary for Health, has said that Hong Kong is developing a rare disease centre in collaborati...
Dr Samantha SHAN, Research Assistant Professor of the School of Optometry of The Hong Kong Polytechnic University (PolyU...
BeiGene, a China-based oncology company, has announced the opening of its flagship US facility in Hopewell, New Jersey, ...
Triastek Inc., a global leader in 3D printing pharmaceuticals, has entered into a research collaboration and platform te...
QingSong Health, a leading health technology platform based in China, has announced a strategic partnership with Globeth...
China-based startup Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and de...
Merck has announced the start of commercial production of its first GMP (Good Manufacturing Practices) compliant manufac...
BioGeometry and Sanyou Bio have jointly announced the signing of a strategic partnership agreement. China-based startup ...
Eisai Co. and Biogen Inc. have announced that the Department of Health in Hong Kong has approved humanised anti-soluble ...
The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) has conducted a large cohort study among ...
Ascentage Pharma has announced that its novel BCR-ABL1 tyrosine kinase inhibitor (TKI), olverembatinib, has been ap...
